What to hopefully look forward too, page-7

HaHa Scott, I didn't find Auspex but I watched it in real time as Stamler led them way past 10x territory. Silently kicking myself for not buying in early. I only really noticed it as the price went ballistic. Teva, the big Israeli generic pharma, bought out Auspex and they kept Stamler and his team on to complete the approval process and drug launch. As you know the Auspex drug has just made blockbuster level for Teva. The indication was for Huntington's, another rare disease. Now that team is running the 202 trial from Vanderbilt university in the USA and that is all good for ATH. It is a worldwide trial and although ATH is well under the radar in the stock market, the MSA community is well aware of the 202 trial results pending in Jan. IMHO.